AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
REported Outcomes in COPD With Trixeo in Real worlD in Germany
Active, not recruiting
- Conditions
- Chronic Obstructive Pulmonary Disease
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 475
- Registration Number
- NCT05311306
- Locations
- 🇩🇪
Research Site, Zirndorf, Germany
Pharmacokinetics, Safety and Efficacy of the Selumetinib Granule Formulation in Children Aged ≥1 to <7 Years With NF1-related Symptomatic, Inoperable PN
Phase 1
Active, not recruiting
- Conditions
- Neurofibromatosis Type 1
- Interventions
- First Posted Date
- 2022-04-04
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT05309668
- Locations
- 🇪🇸
Research Site, Madrid, Spain
Forxiga CKD Japan Post-Marketing Surveillance (PMS)
Completed
- Conditions
- Chronic Kidney Disease
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1029
- Registration Number
- NCT05306210
- Locations
- 🇯🇵
Research Site, Yamanashi, Japan
Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC
Phase 3
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-01-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 760
- Registration Number
- NCT05301842
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Durvalumab
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 61
- Registration Number
- NCT05303532
- Locations
- 🇻🇳
Research Site, Ho Chi Minh, Vietnam
An Observational Prospective Cohort Study for Long-term Management of Hyperkalemia in Patients With Chronic Kidney Disease or Heart Failure
Active, not recruiting
- Conditions
- Hyperkalemia
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2024-05-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 352
- Registration Number
- NCT05297409
- Locations
- 🇯🇵
Research Site, Yamagata, Japan
A Randomised, Open-Label Study to Evaluate the Relative and Absolute Bioavailability of Cotadutide in Healthy Subjects
Phase 1
Completed
- Conditions
- Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus (T2DM)Chronic Kidney Disease
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT05294458
- Locations
- 🇬🇧
Research Site, Ruddington, United Kingdom
AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 46
- Registration Number
- NCT05281601
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
LatInamerican Vaccine Effectiveness Against Hospitalizations Due to Circulating COVID-19 VoC RWE Study
Completed
- Conditions
- COVID-19, SARS-CoV-2
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2024-04-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 792
- Registration Number
- NCT05282017
- Locations
- 🇵🇦
Research Site, Panama, Panama
Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma
- First Posted Date
- 2022-03-10
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 306
- Registration Number
- NCT05274815
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath